Proteostasis sinks after Phase I data for CF triplet therapy

Proteostasis lost $2.76 (68%) to $1.31 on Monday after reporting Phase I data for its triplet cystic fibrosis therapy that lagged behind Phase III data of triple combination CF therapies from Vertex.

Proteostasis Therapeutics Inc. (NASDAQ:PTI) evaluated a triple combo comprising CF transmembrane conductance regulator (CFTR)

Read the full 451 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE